Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: cl who wrote (35)	4/15/1997 12:56:00 AM
From: Miljenko Zuanic	Respond to of 805

Thanks CL. Few days ago I received full package from CTII, but didn't have time to post. Now you mentioned most interesting parts. For chronic and severe pain(cancer or intolerant to any medication) CTII is conducting P IIa phase with three-time increase cell numbers in implants. If this pass, results for controlling the pain will be better, there will be no problem for full P II study. CTII anticipate this in 3Q, with results of the P IIa study by 2Q end. Also, some patients (which survive last stage of the cancer disease longer)have implant for almost one year, no side effects. CTII stock price can move before year-end. Probably, this days CTII will be present in Neurology meeting. My last post in CNSI thread. For other programs will comment later. mz

To: cl who wrote (35)	6/12/1999 1:21:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 805

I am parking this snip from the annual report, and linking it back to the post that got me started on this little subtread...pay me no mind at all...I have not found anything too interesting...yet. In February 1997, the Company and Cognetix, Inc. entered into a Collaboration and Development Agreement to screen selected peptides isolated by Cognetix for possible development into therapeutic roducts aimed at a broad range of human disease states using CytoTherapeutics' encapsulated cell-based delivery technology. The Company and Cognetix have also entered into an option agreement giving the Company the right to option up to three of Cognetix's compounds for use in treating eye diseases. As part of the agreement with Cognetix, CytoTherapeutics had purchased $250,000 of Cognetix preferred stock and, subject to certain milestones, was obligated to purchase up to a total of $1,750,000 of Cognetix's stock over the next year. In July 1997, the Company loaned $250,000 to Cognetix that was repaid with interest in October 1997. In October 1998, the Company sold the $250,000 of preferred stock back to Cognetix for $298,914. The Company and Cognetix are presently discussing proposed revisions to their relationship under the agreements. There is also a four message subthread which begins here which mentions Cognetix: techstocks.com later in the report we have another section... In February 1997, the Company and Cognetix, Inc. entered into a Collaboration and Development Agreement to screen selected peptides isolated by Cognetix for possible development into therapeutic products aimed at a broad range of human disease states using CytoTherapeutic's cell-based technology. Continuation of the agreement is contingent upon meeting an agreed-upon proof of concept test. The companies will generally share expenses associated with the development of any specific product candidate and any resulting revenues, except as otherwise determined on a product-by-product basis. As part of the agreement with Cognetix, the Company purchased $250,000 of Cognetix preferred stock and, subject to certain milestones, was obligated to purchase as much as $1,500,000 of additional Cognetix stock over the next year. In July 1997, the Company loaned $250,000 to Cognetix which was repaid with interest in October 1997. In October 1998, the Company sold the $250,000 of preferred stock back to Cognetix for $298,914. The Company and Cognetix are presently discussing proposed revisions to their relationship under the agreement.